Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 3873599 | [Anti-immunoglobulins (rheumatoid factors)--immunobiology and significance in pediatrics]. | 1985 Apr | Reactions between immunoglobulins and anti-immunoglobulins in adult and juvenile rheumatoid arthritis are reviewed with special respect to juvenile disease. The practical relevance of the different assays is described and future perspectives developed. | |
| 6437412 | Anticollagen antibodies and immune response gene products in rheumatoid arthritis. | 1984 Nov | Circulating antibodies to native and denatured types I and II human and bovine collagens were assayed in patients with rheumatoid arthritis (RA), patients with other rheumatic diseases, and normal individuals. A subgroup of this population was also assayed for reactivity with typing reagents which detect determinants (MT and HLA-DR) present in human immune response gene products. The mean titers of antibodies to each collagen tested were not significantly higher in RA patients when compared with patients who had other rheumatic diseases. Although both MT3 and MT4 were significantly associated with RA, there was no significant association between the anticollagen antibodies and any MT type or HLA-DR4. These studies raise a question concerning the role of collagen antibodies in the pathogenesis of RA and suggest that genes distinct from those coding for HLA-DR may play a role in the expression of the disease. | |
| 3874024 | Detection and partial characterization of human B cell colony stimulating activity in syno | 1985 May | The joint fluids of 37 patients with rheumatoid arthritis, eight patients with traumatic injuries to their joints, two patients with Reiter's syndrome and three patients with psoriatic arthritis were tested for the presence of B cell colony stimulating activity (B cell CSA). B cell CSA was found in all of the joint fluids from the patients with rheumatoid arthritis but in none of the joint fluids from patients with traumatic injuries to their joints or in the joint fluids from the patients with Reiter's syndrome. A trace of B cell CSA was found in the joint fluid of one of the three patients with psoriatic arthritis. There was a positive correlation (r = 0.796) between the amount of rheumatoid factor present in the joint fluids and the titre of B cell CSA. This correlation was highly significant (P less than 0.001). The B cell CSA was localized to component(s) with molecular weight ranges 115-129 kD and 64-72 kD and an isoelectric point of 6.8. Its activity was sensitive to reduction with 2-mercaptoethanol and to the oxidising action of potassium periodate. | |
| 685734 | Taste dysfunction and changes in zinc and copper metabolism during penicillamine therapy f | 1978 | The taste function and the zinc and copper levels in serum and urine were followed for up tp 16 weeks in ten patients who were started on penicillamine therapy for generalized scleroderma (9 patients) and rheumatoid arthritis (one patient). During therapy the serum zinc concentration remained unchanged, whereas the serum copper concentration increased significantly during the first 4--5 weeks and then tended to decrease. Urinary copper rose significantly and remained considerably above the upper normal limit throughout the study. Six of the patients complained after about 4--5 weeks of a decreased taste function, which was gradually restored whether the medication was stopped or continued. The alterations in the taste acuity for sweet, salt, sour, and bitter significantly paralleled the variations in urinary copper before as well as during therapy. Thus, the patients who showed the most pronounced loss of taste, had a lower urinary copper output than those whose taste acuity was less disturbed. | |
| 303378 | Foibles and fallacies in the diagnosis of arthritis. | 1977 Nov | The diagnosis of arthritis is usually made on a clinical basis, and laboratory and x-ray aids are only secondary and sometimes misleading tools. Set forth are 11 common fallacies which often mislead the physician in his interpretation of laboratory and x-ray findings in the study of a patient with arthritis. Included are references to the role of x-ray findings, joint fluid and synovial biopsy findings, hyperuricemia, rheumatoid factor, rheumatoid nodules, sedimentation rate, antinuclear antibodies, and other peripheral blood and urinary findings. In most cases, the astute physician should be able to make an accurate diagnosis when he first sees the arthritic patient; in others, any and all of the laboratory and x-ray parameters mentioned, despite their obvious shortcomings, may be of help in leading to a proper diagnosis. In a small percentage of cases, only the passage of time and further observation of the patient will establish the correct diagnosis. | |
| 7144065 | [Granulocytotoxic antibodies in levamisole-induced agranulocytosis]. | 1982 Oct 15 | Among 98 patients with rheumatoid arthritis who were treated with the immunomodulating agent Levamisole 7 patients developed an agranulocytosis. The ethiology of the Levamisole induced agranulocytosis (LIA) is unknown however circulating granulocytotoxic antibodies are present in the sera of such patients. Routine examination of sera from Levamisole treated patients reveal that such antibodies can be detected several weeks before agranulocytosis in the peripheral blood occurs. Our observation suggest that circulating granulocytotoxic antibodies may play a significant role in the development of LIA and that determinations of such antibodies can provide an excellent tool for the early detection of high risk patients. Routine determinations of such antibodies will allow to increase the safety of this potent agent used in the treatment of rheumatic diseases and Tumors. | |
| 71972 | Flurbiprofen-aspirin interaction: a double-blind crossover study. | 1977 | Fifteen patients with seropositive rheumatoid arthritis were treated for 2-weeks periods with 150 mg flurbiprofen daily and with flubriprofen in the same dosage plus 3 g aspirin daily, the treatments being administered in random allocation. The results showed that there were no significant differences clinically between the two treatments. Serum levels of flurbiprofen were measured during both treatment periods in 4 patients. During the flurbiprofen and aspirin period there was a full in the serum levels of flurbiprofen was unchanged. No obvious reduction in clinical efficacy was apparent. | |
| 1221936 | Xeroradiographic techniques applied to assessment of Achilles tendon in inflammatory or me | 1975 Dec | Ten patients with inflammatory disease (rheumatoid arthritis, ankylosing spondylitis, Reiter's disease) or metabolic disease (gout, pseudogout, tendinous xanthomatosis) affecting the Achilles tendons are presented and discussed. Radiological lateral views of heel were obtained with xeroradiographic techniques, which permitted the recording on the same image of details of both bone and soft tissue and the evaluation and quantification of the changes in the Achilles tendons. Xeroradiography seems to be a very suitable radiological technique for routine use in the evaluation and follow up of rheumatic diseases of the foot. | |
| 3931569 | Serum amyloid A protein (SAA) subtypes in acute and chronic inflammatory conditions. | 1985 Oct | Serum amyloid A (SAA), a polymorphic high density lipoprotein associated plasma protein, is the putative circulating precursor of tissue AA protein fibrils in reactive (secondary) amyloidosis. In the present study we examined the SAA subtype pattern in various acute and chronic inflammatory states in order to find out whether disease-specific SAA isoform profiles exist. The method used to study the subtype pattern is based on electrofocusing of serum followed by immunoblotting. Our results show that the SAA subtype pattern is similar in patients with rheumatoid arthritis with or without amyloid. In addition, in amyloidotic subjects the SAA subtype response to acute tissue injury (arthroplasty) did not differ from that in patients without amyloidosis. Analysis of patients with acute and chronic infectious diseases and non-rheumatic inflammatory conditions showed similar SAA patterns in all subjects. These results suggest that the SAA subtype response to tissue injury and inflammation is similar irrespective of the initiating stimulus. | |
| 6763301 | [Osteoarticular diseases from J.M. Charcot to the present time]. | 1982 | In foreign countries Charcot's main contribution in the field is known as Charcot's joint. A special paper is devoted to this topic by Dr Hubault in this issue of the Revue. It is perhaps less widely known that Charcot's thesis was devoted to rheumatoid arthritis and that he wrote also interesting observations on gout. Pierre Marie gave many famous contributions to bones and joints diseases. In 1886 he described acromegaly. In 1890 he described hypertrophic pulmonary osteoarthropathy which he correctly linked with lung diseases although some of the cases he had collected in the literature were instances of pachydermo-periostosis. In 1900 he gave a brilliant description of achondroplasia in 2 of his patients: Anatole and Claudius. On the 11th of February 1898 he reported 2 patients which were the basis of a historical description of ankylosing spondylitis, on which papers by Strümpell and von Bechterew had appeared in 1884 and 1893. The subsequent works at the Clinique des Maladies du Système Nerveux de la Salpêtrière on sciatica and herniated disks are related in Professor de Seze's paper in this issue of the Revue. | |
| 6678698 | Natural killer cell activity in inflammatory joint disease. | 1983 Sep | The natural killer (NK) cell activity of unfractionated peripheral blood and synovial fluid mononuclear cells from patients with inflammatory joint disease was measured in a short-term assay using the human tumour cell line, K562, as the target. The mean values for peripheral blood NK activity of the various groups (controls, rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA] were similar although the rheumatoid group showed the widest range. However, the NK activity of PsA patients (23.74 +/- 10.14) was significantly lower than that of the controls (31.63 +/- 10.8, 0.05 greater than P greater than 0.01). Almost without exception, NK activity was found to be considerably lower in synovial fluid than in paired blood samples (p less than 0.01). | |
| 6184771 | Protease inhibitors in rheumatoid synovial fluid. Analyses of electrophoretic homogeneity | 1982 | Paired plasma and synovial fluids from 17 patients with seropositive rheumatoid arthritis were examined for electrophoretic homogeneity/heterogeneity and enzymic inhibitory capacity of the protease inhibitors. The high degree of saturation (approximately 90%) of the polyvalent protease inhibitor alpha 2-macroglobulin in the rheumatoid synovial fluid contrasts sharply with the low saturation of alpha 1-anti-trypsin. The inhibitory reactivity of the non-complexed fraction of both of these dominating antiproteases was retained (approximately 85-90%). Thus, a selective inactivation of synovial alpha 1-antitrypsin could not be demonstrated. alpha 1-Anti-chymotrypsin revealed electrophoretic homogeneity in all synovial fluids. Electrophoretic heterogeneity of the plasmin inhibitor antiplasmin was detected in the majority of synovial fluids indicating plasmin activation. The existence of a protease-antiprotease imbalance in the rheumatoid joint was indicated by the high degree of saturation of alpha 2-macroglobulin and a cleavage of C3 in rheumatoid synovial fluids. | |
| 6391796 | Combined disease-modifying chemotherapy for intractable rheumatoid arthritis. | 1984 Aug | When one endeavours to obtain lasting remissions in long-standing or erosive and/or highly seropositive, i.e. unrelenting, RA, combined 'aggressive' two-drug therapy appears to be reasonably well tolerated. Surprisingly, gold and D-penicillamine are not antagonistic but appear to potentiate each other to give the best results. In analogy with lymphoma and with the open trial by McCarty--and in the absence of new major 'disease-modifying' drugs--the door should be kept wide open towards controlled trials of combined three-drug chemotherapy. | |
| 310157 | Incidence of inflammatory rheumatic diseases in Finland. | 1978 | The incidence of inflammatory joint diseases was estimated by using two patient series. Firstly, the total yearly incidence of all such diseases together was estimated in a population of 15 600 persons of 16 years of age or older. Secondly, this overall incidence was divided by the ratio of different diseases obtained from a larger series of patients. The incidence of all inflammatory joint diseases was 218/100 000/year, 182 in males and 250 in females. The incidence was highest in middle age and lowest in old age. The incidence of ill-defined arthritides was five times that of definite rheumatoid arthritis in the youngest age group but in the oldest their frequencies were equal. In the whole population, the proportion of ill-defined arthritides was 2/5, of definite RA 1/5, of HL-A B27 associated diseases 1/5, and of other diseases 1/5 of the total incidence of inflammatory joint diseases. Because the frequency of HL-A B27 in all patients surveyed was about 40%, only half of the patients with this antigen showed a clinical picture of ankylosing spondylitis, Reiter's disease, or reactive arthritis. | |
| 1092726 | Naproxen: long-term study in rheumatoid arthritis and "placebo pulse". | 1975 Apr | Naproxen is by now a relatively well-known antirheumatic drug, and many short-term studies have shown its efficacy and relatively good tolerance. We have observed 64 patients with definite or classical rheumatoid disease, 27 of whom have been followed for well over two years on daily doses of naproxen to ascertain the persistence of drug efficacy and safety. In this part of our study, patients were subjected to complete clinical and biochemical evaluations at two-monthly intervals. Naproxen was well tolerated, and the few side effects reported were transient and mild in nature. Sequential laboratory studies revealed no significant anomaly. Clinical evaluation showed no pattern suggestive of decreasing antirheumatic activity. A question frequently encountered in the treatment of certain diseases such as rheumatoid arthritis is whether long-term improvement is due to efficacious suppressive therapy or spontaneous abatement of disease activity. We devised a double-blind placebo pulse phase in which 19 of our 28 long-term patients participated in a study within a study lasting four weeks. They were divided into two groups. The first group took their usual dose of naproxen during the first two weeks and a corresponding number of placebo tablets in the next two weeks. The procedure was reversed in the other group. We conclude that naproxen remains efficacious. | |
| 7092339 | Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reacti | 1982 Jun | The urinary excretion of sialic-acid-containing oligosaccharides, total sialic acid, serum amyloid A protein (SAA), and C-reactive protein (CRP) has been studied in 48 patients with rheumatoid arthritis (RA) and in 17 patients with systemic lupus erythematosus (SLE). Linear regression analysis revealed a close positive correlation between serum SAA and CRP levels in both RA (r = 0.71, p less than 0.001) and SLE (r = 0.86, p less than 0.001). The urinary excretion of sialyl lactose showed a positive correlation with the serum levels of SAA and CRP in RA (r = 0.45 and r = 0.45, respectively, p less than 0.01) but not in SLE (r = 0.05 and r = 0.10 respectively). Changes in serum total sialic acid levels paralleled those in CRP and SAA in RA as well as in SLE. Patients with very active RA had higher urinary sialyl oligosaccharide excretion (p less than 0.001), higher CRP levels (p less than 0.01), and higher SAA levels ( p less than 0.05) than those with moderately active disease. | |
| 6136256 | Eosinophilia in D-penicillamine therapy. | 1983 Aug | Cross-sectional and longitudinal studies have been carried out to determine the incidence and clinical significance of eosinophilia in patients taking penicillamine for rheumatoid arthritis. In a cross-sectional study of 204 patients eosinophilia was found with equal frequency during treatment with penicillamine, gold, and nonsteroidal anti-inflammatory drugs. A longitudinal study of 89 patients treated with penicillamine showed no consistent relationship between eosinophilia and adverse reactions to the drug. It is concluded that routine monitoring of eosinophil counts is unlikely to be of value in the management of patients taking penicillamine. | |
| 4045842 | IgA containing immune complexes in rheumatoid vasculitis and in active rheumatoid disease. | 1985 Jun | Serum and synovial fluid (SF) from 68 patients with rheumatoid arthritis (RA) were studied for the presence of immune complexes (IC) and the results correlated with extraarticular features and/or disease activity. IC were measured by the 125I Clq binding assay (ClqBA) and with one detecting IgG, IgA, C3 or C4 in IC. Disease activity correlated significantly with IgG or IgA containing and Clq binding IC. The IgA containing IC were found only in 25% of the patients, including all but one case of rheumatoid vasculitis, but otherwise only in seropositive active RA. C3 and C4 IC did not correlated with disease activity, seropositivity or vasculitis. IC in serum did not correlate with SF levels, but C4 containing IC were more frequent in SF (60%) than in serum (30%). Thus serum IC did not reflect SF levels. Patients with vasculitis showed more IC in the sera than in SF. | |
| 2992398 | Abnormal responses of rheumatoid arthritis lymphocytes to Epstein-Barr virus infection in | 1985 Jul | Blood lymphocytes from 53 patients with rheumatoid arthritis (RA) and 44 controls were cultured with the polyclonal B cell activator Epstein-Barr virus (EBV). Culture supernatants were removed at weekly intervals and the amount of IgM secreted by the lymphocytes measured by an enzyme-linked immunosorbent assay (ELISA). Three major differences in the pattern of EBV-induced IgM synthesis by RA versus control lymphocytes were observed. Lymphocytes from RA patients, in general, produced less IgM after one week in culture than controls. In contrast, they increased their IgM secretion significantly by the end of the second week, whereas control lymphocyte cultures showed little change in IgM secretion at this time. Control lymphocytes from EBV seropositive individuals produced undetectable amounts of IgM after five weeks in culture. However, lymphocytes from 40% of the RA patients, even though they were EBV seropositive, secreted greater than 2000 ng/ml (microgram/l) IgM after five weeks. The data are discussed in terms of defective B and T cell responses to EBV in lymphocytes from patients with RA. | |
| 6430907 | The risk of haematogenous infection in total joint replacements. | 1984 Aug | One thousand patients who received 1112 total joint replacements between 1966 and 1980 were followed up prospectively for an average of six years. These patients were not advised to take antibiotics prophylactically to cover subsequent dental or surgical procedures and, so far, only three cases of haematogenous infection at the site of the joint replacement have developed. Two hundred and twenty-four patients did subsequently undergo dental or surgical procedures and 284 patients developed infections in the respiratory tract, urinary tract or at multiple sites; none of these patients developed haematogenous infection. But of 40 patients who suffered recurrent skin ulceration and infection, three (7.5%) developed haematogenous infection of the replaced joint; two of these belonged to a group of 134 patients with rheumatoid arthritis. These results suggest that transient bacteraemia is not likely to infect a replaced joint in otherwise healthy patients. But an infected skin lesion producing chronic bacteraemia, or septicaemia due to a virulent organism, may well do so and patients with rheumatoid arthritis are at greater risk than those with osteoarthritis. |